Mostrar el registro sencillo del ítem

dc.contributor.author
Leone, José Pablo  
dc.contributor.author
Leone, Bernardo Amadeo  
dc.contributor.author
Zwenger, Ariel  
dc.contributor.author
Vallejo, Carlos Teodoro  
dc.contributor.author
Romero, Alberto Omar  
dc.contributor.author
Machiavelli, Mario Raúl  
dc.contributor.author
Pérez, Juan Eduardo  
dc.contributor.author
Leone, Julieta  
dc.date.available
2023-09-15T11:27:12Z  
dc.date.issued
2021-05  
dc.identifier.citation
Leone, José Pablo; Leone, Bernardo Amadeo; Zwenger, Ariel; Vallejo, Carlos Teodoro; Romero, Alberto Omar; et al.; The prognostic significance of metastatic pattern in stage IV male breast cancer at initial diagnosis: a population-based study; Springer; Breast Cancer Research and Treatment; 187; 1; 5-2021; 237-244  
dc.identifier.issn
0167-6806  
dc.identifier.uri
http://hdl.handle.net/11336/211586  
dc.description.abstract
Purpose: Metastatic pattern (MP) is a prognostic factor in women with breast cancer. However, the prognostic significance of MP in male breast cancer patients remains unknown. Methods: Using the SEER database, we gathered demographic information and disease characteristics for men diagnosed with de novo metastatic breast cancer from 2010 to 2017. Metastases to bone, brain, liver, and lung were used to define MP (bone-only, visceral, bone and visceral [BV], or other). Statistical analyses were performed to identify associations between overall survival (OS) and MP, as well as other patient and tumor features. We used multivariate logistic regression to evaluate factors associated with sites of metastases. Results: We included 250 patients. MP distribution was bone = 38.8%, visceral = 14.8%, BV = 33.2%, and other = 13.2%. Median OS for each was bone = 33 months, visceral = 23 months, BV = 20 months, and other = 46 months (p = 0.046). Patients with brain metastases had significantly shorter OS compared with no brain metastases (median OS = 9 months vs. 30 months; p < 0.001). Compared with other subtypes, triple negative had the shortest OS (median 9 months, p < 0.001). Logistic regression modeling revealed that compared with HR+/HER2− breast cancers, HR−/HER2+ had higher odds of liver metastases and triple negative had higher odds of brain metastases. Patients younger than 50 years had a significantly greater risk of developing brain metastases. Conclusions: MP and tumor subtype can predict OS outcomes in men with metastatic breast cancer at diagnosis. Brain metastases confer very poor prognosis.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
Springer  
dc.rights
info:eu-repo/semantics/restrictedAccess  
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/  
dc.subject
BONE METASTASES  
dc.subject
BRAIN METASTASES  
dc.subject
MALE BREAST CANCER  
dc.subject
METASTATIC PATTERN  
dc.subject
PROGNOSTIC FACTORS  
dc.subject
TUMOR SUBTYPE  
dc.subject.classification
Oncología  
dc.subject.classification
Medicina Clínica  
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD  
dc.title
The prognostic significance of metastatic pattern in stage IV male breast cancer at initial diagnosis: a population-based study  
dc.type
info:eu-repo/semantics/article  
dc.type
info:ar-repo/semantics/artículo  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.date.updated
2023-09-13T11:45:39Z  
dc.journal.volume
187  
dc.journal.number
1  
dc.journal.pagination
237-244  
dc.journal.pais
Alemania  
dc.description.fil
Fil: Leone, José Pablo. No especifíca;  
dc.description.fil
Fil: Leone, Bernardo Amadeo. No especifíca;  
dc.description.fil
Fil: Zwenger, Ariel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Patagonia Confluencia; Argentina  
dc.description.fil
Fil: Vallejo, Carlos Teodoro. No especifíca;  
dc.description.fil
Fil: Romero, Alberto Omar. No especifíca;  
dc.description.fil
Fil: Machiavelli, Mario Raúl. No especifíca;  
dc.description.fil
Fil: Pérez, Juan Eduardo. No especifíca;  
dc.description.fil
Fil: Leone, Julieta. No especifíca;  
dc.journal.title
Breast Cancer Research and Treatment  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1007/s10549-020-06052-z